English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Current National Committee for Clinical Laboratory Standards (NCCLS) susceptibility guidelines for quality control testing withHaemophilus influenzae do not include a β-lactamase-producing strain that could detect the deterioration of the β-lactamase inhibitor components of amoxicillin-clavulanic acid, ampicillin-sulbactam, and piperacillin-tazobactam. The objective of the study was to determine if comparable quality control results forEscherichia coli ATCC 35218, a β-lactamase-producing strain, would be produced for the three β-lactam–β-lactamase inhibitor agents with Haemophilus test medium and Mueller-Hinton medium. The criteria used in this study to determine if Haemophilus test medium was acceptable for quality control testing ofE. coli ATCC 35218 was that 100% of the results obtained with an antimicrobial agent-methodology combination needed to be within the acceptable NCCLS ranges established with Mueller-Hinton medium. The MIC testing results obtained by the broth microdilution and E-test methods with amoxicillin-clavulanic acid and piperacillin-tazobactam were all within the NCCLS ranges; however, the results obtained with ampicillin-sulbactam by both methods were not within the NCCLS ranges. Acceptable results were obtained by the disk diffusion methodology with ampicillin-sulbactam and piperacillin-tazobactam but not with amoxicillin-clavulanic acid. When performing susceptibility testing withH. influenzae with the β-lactam–β-lactamase inhibitors, in addition to quality control testing withH. influenzae ATCC 49247, testing ofE. coli ATCC 35218 on Haemophilus test medium is an effective way to monitor the β-lactamase inhibitors in some antimicrobial agent-methodology combinations.

antimicrobial agents and chemotherapy

<i>Escherichia coli</i> ATCC 35218 as a Quality Control Isolate for Susceptibility Testing of <i>Haemophilus influenzae</i> with Haemophilus Test Medium

Escherichia coli ATCC 35218 as a Quality Control Isolate for Susceptibility Testing of Haemophilus influenzae with Haemophilus Test Medium